Connor, Clark & Lunn Investment Management Ltd. Castle Biosciences Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$20 Billion
Q4 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 168,713 shares of CSTL stock, worth $3.36 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

168,713

Previous 165,458 1.97%

Holding current value

$3.36 Million

Previous $4.72 Million 4.71%

% of portfolio

0.02%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$26.52 - $34.67 $86,322 - $112,850	3,255 Added 1.97%	168,713 $4.5 Million
Q3 2024 Nov 08, 2024	BUY	$17.4 - $31.47 $1.72 Million - $3.1 Million	98,571 Added 147.37%	165,458 $4.72 Million
Q2 2024 Aug 09, 2024	SELL	$18.84 - $24.94 $202,906 - $268,603	-10,770 Reduced 13.87%	66,887 $1.46 Million
Q1 2024 May 09, 2024	SELL	$18.06 - $25.3 $197,088 - $276,098	-10,913 Reduced 12.32%	77,657 $1.72 Million
Q4 2023 Feb 09, 2024	BUY	$12.19 - $22.43 $97,337 - $179,103	7,985 Added 9.91%	88,570 $1.91 Million
Q3 2023 Nov 13, 2023	BUY	$13.28 - $20.3 $252,851 - $386,512	19,040 Added 30.94%	80,585 $1.36 Million
Q2 2023 Aug 10, 2023	BUY	$11.66 - $26.0 $225,772 - $503,438	19,363 Added 45.9%	61,545 $844,000
Q1 2023 May 09, 2023	BUY	$19.47 - $28.49 $273,319 - $399,942	14,038 Added 49.88%	42,182 $958,000
Q4 2022 Feb 10, 2023	BUY	$18.08 - $30.0 $91,358 - $151,590	5,053 Added 21.88%	28,144 $662,000
Q3 2022 Nov 10, 2022	BUY	$22.51 - $34.32 $81,666 - $124,512	3,628 Added 18.64%	23,091 $602,000
Q2 2022 Aug 05, 2022	BUY	$16.0 - $45.99 $311,408 - $895,103	19,463 New	19,463 $427,000

Others Institutions Holding CSTL

# of Institutions

209

Shares Held

25.9M

Call Options Held

128K

Put Options Held

35.4K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $524M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Castle Biosciences Inc Transaction History